Home News

ROVI and the EIB agreement

ROVI and the EIB agree to sign a loan to boost research into drug administration and prolonged-release technologies

Thu, 21/12/2017 - 18:33 0 min
No votes yet
 
Related
First nine months 2024 results press release
Operating revenue in the first nine months of 2024 was 564.6 million euros, a 5% decrease on the first nine months of 2023, mainly due...
4 min
07/11/2024
ROVI completes the strategic review of its CDMO business
Madrid, Spain - 24 October 2024 – Laboratorios Farmacéuticos Rovi, S.A. (hereinafter, “ROVI”), a pan-European pharmaceutical company that...
2 min
24/10/2024
First half 2024 results press release
ROVI ACHIEVED OPERATING REVENUE OF 329.3 MILLION EUROS AND INCREASED ITS GROSS MARGIN BY 2.8 PERCENTAGE POINTS Operating revenue in...
7 min
31/07/2024